 This is a double-blind neither investigator nor participant knows which treatment the participant receives, placebo-controlled placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial, randomized study medication assigned to participants by chance, prospective study following patients forward in time study. The total study duration for each participant will be approximately 48 days. The study will consist of 3 parts: Screening Phase 5 days and double-blind treatment Phase from Day 1 to 21, consists of Phase-1 and Phase-2 and follow-up Phase from Day 21 to 43. Participants will receive mebendazole 600 milligram mg and quinfamide 200 mg tablets orally once starting on Day 1 and mebendazole 600 mg and quinfamide 200 mg or placebo tablets orally once starting on Day 21. Efficacy will be primarily evaluated by percentage of participants with eradication of helminthic andor protozoa. Participants safety will be monitored throughout the study. 